What Is Lutetium-177? PSMA, PRRT and Theranostics

Lutetium-177 is a beta-emitting radionuclide used in targeted radiopharmaceutical therapies. It delivers radiation to cells that express the target recognized by the attached molecule.

No. Lu-177 therapy is targeted radioligand or radionuclide treatment, not conventional cytotoxic chemotherapy.

The phrase can be misleading: PSMA PET or DOTATATE PET images the target before treatment; Lu-177 is mainly the treatment isotope. Post-therapy SPECT or gamma camera imaging may be performed.

It can treat selected patients with PSMA-positive metastatic castration-resistant prostate cancer. Regulatory indications vary between countries.

Yes. Lu-177 DOTATATE is used for selected somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors as PRRT; it is not the same medicine as Lu-177 PSMA.

Both carry Lu-177 but target different receptors: PSMA on selected prostate cancers and somatostatin receptors on certain neuroendocrine tumors.

It is not a guaranteed cure. It may improve disease control or symptoms, with outcomes varying by tumor biology and treatment history.

Suitable PSMA PET imaging is important to confirm target expression before PSMA radioligand therapy. The treatment team chooses the appropriate test.

Somatostatin receptor PET can help show whether a tumor is target-positive for PRRT; PET imaging itself is not the treatment.

An authorized nuclear medicine team administers the radiopharmaceutical intravenously with radiation safety measures. Preparation and monitoring depend on the product.

There may be a brief needle sting. The infusion itself is generally not painful like surgery, but symptoms should be reported.

Infusion time differs from the full visit. Product, hydration, observation and local radiation discharge rules determine the total duration.

A common approved Lu-177 PSMA-617 regimen is up to six doses at six-week intervals. Lu-177 DOTATATE has a different four-dose, eight-week regimen. Plans are individualized.

There is no single fasting rule for every product. Follow the specific nuclear medicine facility instructions.

Blood count, kidney function and sometimes liver tests are commonly reviewed, with additional tests based on medical history.

Kidney function and product matter. Reduced function may increase risk and requires careful individualized assessment.

Anemia or low platelets/white cells can require delaying, adjusting or withholding treatment, depending on severity.

Fatigue, nausea, dry mouth, appetite changes and low blood counts can occur. Serious marrow and kidney toxicity are also possible.

Kidney toxicity is a potential risk. Renal function is checked before and during follow-up.

Some PSMA-targeted agents also accumulate in salivary glands, potentially causing dry mouth or taste changes.

There may temporarily be external radiation and contamination risk from bodily fluids. Follow written distance, time and hygiene instructions.

Duration depends on product, administered activity, measurements and local rules. Follow individualized radiation safety instructions.

Treatment can be outpatient in some settings, while isolation or admission may be required elsewhere under local rules.

Hydration and frequent urination are commonly advised, but fluid restrictions must be respected in heart or kidney disease.

Yes. Because radioactivity can be excreted in urine, follow the hygiene and cleaning instructions supplied by radiation safety staff.

Some patients may drive if they had no sedation or impairing symptoms; verify with the team.

Radiation detectors may react temporarily. Inform your team about travel and obtain documentation when appropriate.

Fever, shortness of breath, uncontrolled bleeding, marked decrease in urine, fainting or severe deterioration requires urgent assessment.

Response is assessed using PSA, laboratory tests, symptoms and appropriate imaging rather than any single result.

Follow-up may include PSMA PET/CT, CT, MRI or other scans; immediate post-therapy imaging may instead use SPECT.

Unlike a laboratory test, response unfolds over multiple cycles and is assessed by tests, symptoms and scans.

A PSA decline may be encouraging but is not sufficient alone; imaging and clinical findings also matter.

Hair thinning or loss can occur in some patients but is not universal; previous therapies may contribute.

Radiopharmaceuticals may affect fertility. Discuss family planning and contraception duration with your team and the product information.

No. Lu-177 is systemic targeted radiopharmaceutical therapy, whereas external beam radiation is delivered from a machine outside the body.

Lu-177 emits beta particles and Ac-225 alpha particles. Evidence, safety, access and regulatory status differ.

No. Eligibility depends on disease stage, prior treatments, PSMA PET findings, organ function and local approval.

It is not routine first-line treatment for early localized prostate cancer. Research uses should be distinguished from approved indications.

In March 2025 the US FDA expanded the indication for selected PSMA-positive mCRPC patients suitable for delaying taxane chemotherapy. This does not automatically apply in other countries.

It is used for certain somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, not all cancers.

Lu-177 DOTATATE protocols use amino acid solutions to reduce renal radiation exposure; this is not the same as every Lu-177 PSMA protocol.

PSMA PET is diagnostic imaging while Lu-177 PSMA delivers therapeutic radiation to the target; they are distinct procedures.

Alternatives may include hormonal agents, chemotherapy, radiotherapy, targeted drugs or other radiopharmaceuticals depending on disease.

Lu-177 is administered in appropriately authorized nuclear medicine facilities. Contact Anka Sağlık Hizmetleri for information and confirm actual availability and location before travel.

Costs depend on product, cycles, imaging, laboratory testing, admission and insurance. Obtain a verified written quote.

Coverage depends on local policy, indication, facility agreements and insurance. Verify authorization in advance.

Before traveling from surrounding provinces, confirm medical review, appointment availability, lodging, escort needs and radiation safety requirements.

Pathology, treatment history, laboratory results, relevant PET imaging and medication list may be requested.

Household arrangements depend on personalized radiation discharge instructions; there is no universal yes/no rule.

Contact the treating facility, and seek emergency help for severe breathing difficulty, bleeding or altered consciousness.

Lu-177 has a physical half-life of about 6.65 days; biological clearance varies by patient and product.

No. Target expression, tumor burden, prior therapy, marrow/renal reserve and clinical condition influence outcomes.